Back
Prelude Therapeutics Stock Price Chart
Sponsored
PRLD
Sponsored
"The Next Apple?" - Mode's Growth Story is Turning Heads
This is a paid advertisement for Mode Mobile Regulation A offering. Please read the offering circular and related risks at invest.modemobile.com.
Sell
1
PRLD
Prelude Therapeutics
Last Price:
2.56
Seasonality Move:
-34.13%
7 Day Trial
ALL ACCESS PASS
$
7
Hint at where the next big move in the market will be this month
Spot the next big move with this free book from a hedge fund manager- Based on the share price being below its 5, 20 & 50 day exponential moving averages, the current trend is considered strongly bearish and PRLD is experiencing selling pressure, which indicates risk of future bearish movement.
Prelude Therapeutics Price Chart Indicators
Moving Averages | Level | Buy or Sell |
---|---|---|
8-day SMA: | 3.8 | Sell |
20-day SMA: | 4.67 | Sell |
50-day SMA: | 5.13 | Sell |
200-day SMA: | 4.23 | Sell |
8-day EMA: | 3.45 | Sell |
20-day EMA: | 4.31 | Sell |
50-day EMA: | 4.7 | Sell |
200-day EMA: | 4.45 | Sell |
Prelude Therapeutics Technical Analysis Indicators
Chart Indicators | Level | Buy or Sell |
---|---|---|
MACD (12, 26): | -0.63 | Sell |
Relative Strength Index (14 RSI): | 27.29 | Sell |
Chaikin Money Flow: | -252529 | - |
Bollinger Bands | Level | Buy or Sell |
---|---|---|
Bollinger Bands (25): | (3.8 - 5.84) | Sell |
Bollinger Bands (100): | (3.55 - 5.41) | Sell |
Prelude Therapeutics Technical Analysis
Sep 5 | Sep 6 | Sep 9 | Sep 10 | Sep 11 | Sep 12 | Sep 13 | Sep 16 | Sep 17 | Sep 18 | |
---|---|---|---|---|---|---|---|---|---|---|
Sep | ||||||||||
05 | 06 | 09 | 10 | 11 | 12 | 13 | 16 | 17 | 18 | |
Technical Analysis: Buy or Sell? | ||||||||||
8-day SMA: | ||||||||||
20-day SMA: | ||||||||||
50-day SMA: | ||||||||||
200-day SMA: | ||||||||||
8-day EMA: | ||||||||||
20-day EMA: | ||||||||||
50-day EMA: | ||||||||||
200-day EMA: | ||||||||||
MACD (12, 26): | ||||||||||
Relative Strength Index (14 RSI): | ||||||||||
Bollinger Bands (25): | ||||||||||
Bollinger Bands (100): |
Technical Analysis for Prelude Therapeutics Stock
Is Prelude Therapeutics Stock a Buy?
- Prelude Therapeutics share price is 2.44 while PRLD 8-day simple moving average is 3.80, which is a Sell signal.
- The stock price of PRLD is 2.44 while Prelude Therapeutics 20-day SMA is 4.67, which makes it a Sell.
- Prelude Therapeutics 50-day simple moving average is 5.13 while PRLD share price is 2.44, making it a Sell technically.
- PRLD stock price is 2.44 and Prelude Therapeutics 200-day simple moving average is 4.23, creating a Sell signal.
PRLD Technical Analysis vs Fundamental Analysis
Sell
1
Prelude Therapeutics (PRLD)
is a Sell
Is Prelude Therapeutics a Buy or a Sell?
-
Prelude Therapeutics stock is rated a Sell
The current Prelude Therapeutics [PRLD] share price is $2.44. The Score for PRLD is 1, which is 98% below its historic median score of 50, and infers higher risk than normal.
Prelude Therapeutics Stock Info
Market Cap:
134.26M
Price in USD:
2.44
Share Volume:
442.4K
Prelude Therapeutics 52-Week Range
52-Week High:
6.80
52-Week Low:
1.66
Sell
1
Prelude Therapeutics (PRLD)
is a Sell
Prelude Therapeutics Share Price Forecast
-
What is the Prelude Therapeutics stock price today?
The Prelude Therapeutics stock price is 2.44 USD today. -
Will PRLD stock go up or go down?
Prelude Therapeutics> share price is forecast to RISE/FALL based on technical indicators -
Is Prelude Therapeutics overvalued?
According to simple moving average, exponential moving average, oscillators, and other technical indicators, Prelude Therapeutics is overvalued.
Is Prelude Therapeutics Stock a Buy?
- Prelude Therapeutics share price is 2.44 while PRLD 8-day exponential moving average is 3.45, which is a Sell signal.
- The stock price of PRLD is 2.44 while Prelude Therapeutics 20-day EMA is 4.31, which makes it a Sell.
- Prelude Therapeutics 50-day exponential moving average is 4.70 while PRLD share price is 2.44, making it a Sell technically.
- PRLD stock price is 2.44 and Prelude Therapeutics 200-day simple moving average is 4.45, creating a Sell signal.
Fundamental Analysis of Prelude Therapeutics
Is Prelude Therapeutics a good investment?
- Analysts estimate an earnings increase this quarter of $0.12 per share, an increase next quarter of $0.02 per share, an increase this year of $0.22 per share, and an increase next year of $0.21 per share.
Technical Analysis of Prelude Therapeutics
Should I short Prelude Therapeutics stock?
- PRLD Moving Average Covergence Divergence (MACD) indicator is -0.63, suggesting Prelude Therapeutics is a Sell
- Prelude Therapeutics Relative Strength Index (RSI) is 27.29, which suggest Prelude Therapeutics is oversold
- The Bollinger Bands (25) for Prelude Therapeutics is (3.8 - 5.84), which suggest Prelude Therapeutics is a Sell
- The Bollinger Bands (100) for Prelude Therapeutics is (3.55 - 5.41), which suggest Prelude Therapeutics is a Sell
* Prelude Therapeutics stock forecasts short-term for next days and weeks may differ from long term prediction for next month and year based on timeline differences.